Intranasal COVID Vaccine Gets DCGA Emergency Use Authorisation

Intranasal COVID Vaccine Gets DCGA Emergency Use Authorisation

  • Research Stash
  • News
  • 2.7K

The Department of Biotechnology and its PSU, Biotechnology Industry Research Assistance Council, on Wednesday announced that the Drug Controller General of India had given emergency use authorization for the first-of-its-kind intranasal COVID-19 vaccine developed by Bharat Biotech.

The development of the vaccine was supported by DBT and BIRAC under the aegis of Mission COVID Suraksha. DBT launched the mission, and BIRAC implemented it to reinforce and accelerate COVID-19 vaccine development efforts as part of the Aatmanirbhar 3.0 programme. This is the fourth success story for the COVID-19 vaccine under mission COVID Suraksha.

Named BBV154, it is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vector vaccine. It consists of a replication-deficient ChAd vector expressing the stabilized Spike SARS-CoV-2 (Wuhan variant).

DBT’s Autonomous Institute, National Institute of Immunology (NII), New Delhi, used its Human Immune Monitoring and T-cell Immunoassay platform to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses in the trial participants. Interactive Research School for Health Affairs, Pune, completed the Plaque Reduction Neutralization Assay to quantify the titre of neutralizing antibodies for the virus from three trial sites.

Commenting on the development, Dr. Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, “The Department, through Mission COVID Suraksha, is committed to the development of safe and efficacious COVID-19 vaccines. BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group, for restricted use in an emergency. An excellent example of the Aatmanirbharta initiative of the Government of India. I congratulate our scientists for partnering with Bharat Biotech and supplying scientific leadership throughout the development of the vaccine”. (ISW)

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook

Rate

DBT’s Autonomous Institute, National Institute of Immunology (NII), New Delhi, used its Human Immune Monitoring and T-cell Immunoassay platform to examine the vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immune responses in the trial participants. Interactive Research School for Health Affairs, Pune, completed the Plaque Reduction Neutralization Assay to quantify the titre of neutralizing antibodies for the virus from three trial sites.

Commenting on the development, Dr. Rajesh S Gokhale, Secretary, DBT, and Chairperson, BIRAC, said, “The Department, through Mission COVID Suraksha, is committed to the development of safe and efficacious COVID-19 vaccines. BBV154 COVID Vaccine is the first intranasal vaccine approved by DCGI for primary immunization against COVID-19 in the 18+ age group, for restricted use in an emergency. An excellent example of the Aatmanirbharta initiative of the Government of India. I congratulate our scientists for partnering with Bharat Biotech and supplying scientific leadership throughout the development of the vaccine”. (ISW)

If you liked this article, then please subscribe to our YouTube Channel for the latest Science & Tech news. You can also find us on Twitter & Facebook

" }
Scientists Develop Database of Everyday Harmful Chemicals

Scientists Develop Database of Everyday Harmful Chemicals

Scientists have developed a comprehensive database of such chemicals belonging to a particular category known as endocrine-disrupting chemicals or EDCs

  • News
  • 1.3K
Read more

Quantum Dots Make the Leap from TVs to Antibacterial Eye Drops

Quantum dots are transforming electronic displays on TVs and tablets. But now, one group reports in ACS Nano that these tiny structures may someday provide relief for eye infections resulting from contact lens wear, trauma or some types of surgeries.

  • News
  • 1.4K
Read more
CSIR-CFTRI’s Protein-Enriched Biscuits Reach COVID-19 Patients

CSIR-CFTRI’s Protein-Enriched Biscuits Reach COVID-19 Patients

The Mysuru-based CSIR-Central Food Technological Research Institute has supplied high-protein biscuits to the COVID-19 patients undergoing treatment in the All India Institute of Medical Science

  • News
  • 1.3K
Read more

Internet is huge! Help us find great content

Newsletter

Never miss a thing! Sign up for our newsletter to stay updated.

About

Research Stash is a curated collection of tools and News for S.T.E.M researchers

Have any questions or want to partner with us? Reach us at hello@researchstash.com

Navigation

Submit